Prelude Therapeutics Price Target Increased 29.17% to $5.27

Prelude Therapeutics' (PRLD) average one-year price target has been increased to $5.27 per share, a 29.17% rise from the previous estimate of $4.08. The target is based on analysts' forecasts and represents a 62.66% increase from the latest closing price of $3.24. The number of funds reporting positions in PRLD has decreased by 36, or 41.38%, to 51, with an average portfolio weight of 0.02%.